Condition: Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma · Sponsor: Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Squamous cell carcinoma of the head and neck (SCCHN) arises from epithelial cells and occurs in the oral cavity, pharynx and larynx. SCCHN is the seventh most common cancer worldwide with an annual incidence of approximately 90.000 cases per year in Europe. Recurrent / metastatic SCCHN remains a grievous diagnosis and optimal treatment options after progression to first-line ICI treatment are not determined yet. Previous reports showed that cetuximab plus paclitaxel after progression to ICI therapy may have an enhanced activity as second line after ICI therapy ERBIOTAX is multi-center, open-label, randomized, non-comparative two-arm, phase 2 trial Investigator Initiated Study. The primary study aims is to evaluate the efficacy of weekly cetuximab combined with paclitaxel (Arm A) or cetuximab monotherapy (Arm B) after progression to pembrolizumab plus platinum / 5-FU. The efficacy of treatment will be assessed through objective response rate (ORR). Patients will be randomized in a 2:1 ratio to ERBITAX (cetuximab + paclitaxel) and cetuximab, respectively, assigning 2 patients to Arm A and 1 patient to Arm B out of 3 patients. No stratification for the randomization process is planned as this is a non-comparative study. A total of 65 evaluable patients will be included in the trial; 41 in Arm A and 24 in Arm B. The main hypothesis is that treatment with the cetuximab +/- paclitaxel regimen maybe more effective after immune checkpoint inhibitors (ICI) failure in patients with…
This description comes directly from the study's public registry record.
Federico Nepote, M.D., PhD. · +34 93 434 44 12 · investigacio@mfar.net
Marisa Duran Senior Clinical research proyect manager (TTCC) · 0034690756714 · mduran@ttccgrupo.com
Always discuss trial participation with your own doctor first.
| Hospital Clínico Universitario de Santiago de Compostela | Santiago de Compostela, A Coruña, Spain | Recruiting |
| Instituto Catalán de Oncología - Badalona | Badalona, Barcelona, Spain | Recruiting |
| Instituto Catalán de Oncología - Hospital Duran i Reynals | Barcelona, Barcelona, Spain | Recruiting |
| Hospital Universitario Marqués de Valdecilla (Santander) | Santander, Cantabria, Spain | Recruiting |
| Hospital Universitario Virgen de las Nieves | Granada, Granada, Spain | Recruiting |
| Centro Oncológico de Galicia (La Coruña) | A Coruña, La Coruña, Spain | Recruiting |
| Hospital Universitario Lucus Augusti | Lugo, Lugo, Spain | Recruiting |
| Hospital Clínico San Carlos | Madrid, Madrid, Spain | Recruiting |
| Hospital Universitario 12 de Octubre (Madrid) | Madrid, Madrid, Spain | Withdrawn |
| Hospital Infanta Leonor (Madrid) | Vallecas, Madrid, Spain | Recruiting |
| Hospital Regional Universitario de Málaga | Málaga, Málaga, Spain | Recruiting |
| Complejo Hospitalario de Navarra (Pamplona) | Pamplona, Navarre, Spain | Recruiting |
+ 5 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06856213